• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks Whale Activity In Today's Session

    7/23/24 1:35:23 PM ET
    $ALGN
    $BSX
    $DHR
    $EVH
    Industrial Specialties
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ALGN alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels.

    Here's the list of options activity happening in today's session:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    BSX PUT SWEEP BEARISH 08/16/24 $75.00 $68.9K 5.5K 2.1K
    MRNA CALL SWEEP NEUTRAL 11/15/24 $170.00 $121.7K 4.9K 1.2K
    EVH CALL SWEEP BEARISH 01/17/25 $20.00 $28.7K 3.5K 1.0K
    DHR PUT SWEEP BULLISH 10/18/24 $240.00 $72.6K 158 867
    ALGN PUT SWEEP BEARISH 07/26/24 $225.00 $25.9K 509 343
    NVAX CALL TRADE BULLISH 01/17/25 $10.00 $100.5K 9.3K 313
    ZVRA CALL SWEEP BEARISH 11/15/24 $7.50 $38.7K 3.8K 253
    TMO PUT TRADE BULLISH 07/26/24 $550.00 $77.4K 316 250
    IOVA PUT TRADE BULLISH 01/17/25 $9.00 $33.0K 502 150
    PFE CALL TRADE NEUTRAL 06/20/25 $23.00 $69.0K 1.1K 103

    Explanation

    These bullet-by-bullet explanations have been constructed using the accompanying table.

    • For BSX (NYSE:BSX), we notice a put option sweep that happens to be bearish, expiring in 24 day(s) on August 16, 2024. This event was a transfer of 811 contract(s) at a $75.00 strike. This particular put needed to be split into 47 different trades to become filled. The total cost received by the writing party (or parties) was $68.9K, with a price of $85.0 per contract. There were 5564 open contracts at this strike prior to today, and today 2101 contract(s) were bought and sold.

    • Regarding MRNA (NASDAQ:MRNA), we observe a call option sweep with neutral sentiment. It expires in 115 day(s) on November 15, 2024. Parties traded 234 contract(s) at a $170.00 strike. This particular call needed to be split into 22 different trades to become filled. The total cost received by the writing party (or parties) was $121.7K, with a price of $520.0 per contract. There were 4997 open contracts at this strike prior to today, and today 1291 contract(s) were bought and sold.

    • For EVH (NYSE:EVH), we notice a call option sweep that happens to be bearish, expiring in 178 day(s) on January 17, 2025. This event was a transfer of 87 contract(s) at a $20.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $28.7K, with a price of $330.0 per contract. There were 3588 open contracts at this strike prior to today, and today 1000 contract(s) were bought and sold.

    • Regarding DHR (NYSE:DHR), we observe a put option sweep with bullish sentiment. It expires in 87 day(s) on October 18, 2024. Parties traded 330 contract(s) at a $240.00 strike. This particular put needed to be split into 35 different trades to become filled. The total cost received by the writing party (or parties) was $72.6K, with a price of $220.0 per contract. There were 158 open contracts at this strike prior to today, and today 867 contract(s) were bought and sold.

    • Regarding ALGN (NASDAQ:ALGN), we observe a put option sweep with bearish sentiment. It expires in 3 day(s) on July 26, 2024. Parties traded 54 contract(s) at a $225.00 strike. This particular put needed to be split into 11 different trades to become filled. The total cost received by the writing party (or parties) was $25.9K, with a price of $480.0 per contract. There were 509 open contracts at this strike prior to today, and today 343 contract(s) were bought and sold.

    • Regarding NVAX (NASDAQ:NVAX), we observe a call option trade with bullish sentiment. It expires in 178 day(s) on January 17, 2025. Parties traded 150 contract(s) at a $10.00 strike. The total cost received by the writing party (or parties) was $100.5K, with a price of $670.0 per contract. There were 9360 open contracts at this strike prior to today, and today 313 contract(s) were bought and sold.

    • For ZVRA (NASDAQ:ZVRA), we notice a call option sweep that happens to be bearish, expiring in 115 day(s) on November 15, 2024. This event was a transfer of 250 contract(s) at a $7.50 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $38.7K, with a price of $155.0 per contract. There were 3801 open contracts at this strike prior to today, and today 253 contract(s) were bought and sold.

    • For TMO (NYSE:TMO), we notice a put option trade that happens to be bullish, expiring in 3 day(s) on July 26, 2024. This event was a transfer of 90 contract(s) at a $550.00 strike. The total cost received by the writing party (or parties) was $77.4K, with a price of $860.0 per contract. There were 316 open contracts at this strike prior to today, and today 250 contract(s) were bought and sold.

    • Regarding IOVA (NASDAQ:IOVA), we observe a put option trade with bullish sentiment. It expires in 178 day(s) on January 17, 2025. Parties traded 150 contract(s) at a $9.00 strike. The total cost received by the writing party (or parties) was $33.0K, with a price of $220.0 per contract. There were 502 open contracts at this strike prior to today, and today 150 contract(s) were bought and sold.

    • Regarding PFE (NYSE:PFE), we observe a call option trade with neutral sentiment. It expires in 332 day(s) on June 20, 2025. Parties traded 100 contract(s) at a $23.00 strike. The total cost received by the writing party (or parties) was $69.0K, with a price of $690.0 per contract. There were 1193 open contracts at this strike prior to today, and today 103 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more news on unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALGN
    $BSX
    $DHR
    $EVH

    CompanyDatePrice TargetRatingAnalyst
    Pfizer Inc.
    $PFE
    2/20/2026$25.00Underweight
    Barclays
    Pfizer Inc.
    $PFE
    2/12/2026$27.00Outperform → Neutral
    Daiwa Securities
    Align Technology Inc.
    $ALGN
    2/9/2026$200.00Hold → Buy
    HSBC Securities
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    Pfizer Inc.
    $PFE
    1/7/2026$25.00Neutral
    UBS
    Moderna Inc.
    $MRNA
    1/7/2026$34.00Neutral
    UBS
    Moderna Inc.
    $MRNA
    12/12/2025$30.00Hold
    Jefferies
    Thermo Fisher Scientific Inc
    $TMO
    12/11/2025$660.00Neutral → Buy
    Citigroup
    More analyst ratings

    $ALGN
    $BSX
    $DHR
    $EVH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Pfizer with a new price target

    Barclays initiated coverage of Pfizer with a rating of Underweight and set a new price target of $25.00

    2/20/26 8:25:15 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pfizer downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Pfizer from Outperform to Neutral and set a new price target of $27.00

    2/12/26 7:23:25 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Align Tech upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded Align Tech from Hold to Buy and set a new price target of $200.00

    2/9/26 6:58:22 AM ET
    $ALGN
    Industrial Specialties
    Health Care

    $ALGN
    $BSX
    $DHR
    $EVH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALGN
    $BSX
    $DHR
    $EVH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Springstubb Brendan B bought $38,199 worth of shares (10,000 units at $3.82), increasing direct ownership by 20% to 58,821 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    11/19/25 4:23:02 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Director Favorito Tamara A bought $24,718 worth of shares (3,175 units at $7.79), increasing direct ownership by 442% to 3,894 units (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    9/16/25 4:15:37 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Shih Alvin bought $157,800 worth of shares (20,000 units at $7.89) (SEC Form 4)

    4 - ZEVRA THERAPEUTICS, INC. (0001434647) (Issuer)

    9/15/25 4:07:29 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALGN
    $BSX
    $DHR
    $EVH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CHIEF FINANCIAL OFFICER Morici John sold $1,508,646 worth of shares (7,969 units at $189.31), decreasing direct ownership by 49% to 8,237 units (SEC Form 4)

    4 - ALIGN TECHNOLOGY INC (0001097149) (Issuer)

    2/20/26 7:59:35 PM ET
    $ALGN
    Industrial Specialties
    Health Care

    Executive Vice President Milosevich Gregory M exercised 1,320 shares at a strike of $58.59 and sold $274,575 worth of shares (1,320 units at $208.01) (SEC Form 4)

    4 - DANAHER CORP /DE/ (0000313616) (Issuer)

    2/20/26 5:00:11 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    EVP and CFO Monson Jonathan covered exercise/tax liability with 1,698 shares and converted options into 3,814 shares, increasing direct ownership by 6% to 37,986 units (SEC Form 4)

    4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)

    2/18/26 5:58:53 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $ALGN
    $BSX
    $DHR
    $EVH
    SEC Filings

    View All

    SEC Form S-8 filed by Moderna Inc.

    S-8 - Moderna, Inc. (0001682852) (Filer)

    2/20/26 4:03:07 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Moderna Inc.

    10-K - Moderna, Inc. (0001682852) (Filer)

    2/20/26 4:02:04 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Boston Scientific Corporation

    10-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)

    2/17/26 4:08:52 PM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    $ALGN
    $BSX
    $DHR
    $EVH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 10:30 a.m. EST. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days. About Pfizer: Breakthrough

    2/23/26 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boston Scientific elects Cathy Smith and Christophe Weber to Board of Directors

    MARLBOROUGH, Mass., Feb. 23, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) announced today the election of Cathy Smith and Christophe Weber to its Board of Directors, effective February 18, 2026. Smith is a seasoned executive with deep expertise in finance, corporate strategy and operational excellence. She currently serves as chief financial officer of Starbucks. Previously, she held chief financial officer roles at Nordstrom, Bright Health, Target, Express Scripts and Walmart, supporting large, complex organizations through periods of significant growth. Smith

    2/23/26 8:00:00 AM ET
    $BSX
    Medical/Dental Instruments
    Health Care

    Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

    SAN CARLOS, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on February 19, 2026 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 3,600 shares of Iovance's common stock to two new, non-executive employees. The awards were granted under Iovance's Amended and Restated 2021 Inducement Plan, which was adopted on September 22, 2021 and amended and restated on January 12, 2022, March 13,

    2/20/26 5:15:00 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALGN
    $BSX
    $DHR
    $EVH
    Leadership Updates

    Live Leadership Updates

    View All

    Danaher To Acquire Masimo Corporation

    WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Masimo Corporation (NASDAQ:MASI) a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings. Under the terms of the agreement, Danaher will acquire all of the outstanding shares of Masimo common stock for $180 per share in cash, or a total enterprise value of approximately $9.9 billion including assumed indebtedness and net of acquired cash. This represents a transaction multiple of approximately 18x estimated 2027 EBITDA, or 15x 2

    2/17/26 8:00:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    $ALGN
    $BSX
    $DHR
    $EVH
    Financials

    Live finance-specific insights

    View All

    Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 10:30 a.m. EST. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days. About Pfizer: Breakthrough

    2/23/26 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    GAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 26, 2026. Details of the event and replay are as follows:Conference call details:Date:February 26, 2026Time:8:30 a.m. ETURL to register phone:Register HereDial-in number:(888) 880-3330 (U.S.) or(+1) (646) 357-8766 (International)Webcast:ir.novavax.com/eventsParticipants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants can als

    2/19/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Masimo to be Acquired by Danaher for $180.00 Per Share

    Masimo Corporation (NASDAQ:MASI) ("Masimo"), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE:DHR) ("Danaher") will acquire Masimo for $180.00 per share in cash, representing a total consideration of $9.9 billion (the "Transaction"). The Transaction has been unanimously approved by both Masimo's Board of Directors and Danaher's Board of Directors. Masimo will become a standalone business unit and brand within Danaher's Diagnostics segment and will operate autonomously while strengthening Danaher's offering in acute care settings. Katie Szyman, Chief Executive Officer of Masimo, stated: "We loo

    2/17/26 8:02:00 AM ET
    $DHR
    $MASI
    Industrial Machinery/Components
    Industrials
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ALGN
    $BSX
    $DHR
    $EVH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc.

    SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

    11/14/24 4:50:30 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Zevra Therapeutics Inc.

    SC 13G - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

    11/14/24 1:00:16 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zevra Therapeutics Inc.

    SC 13G/A - ZEVRA THERAPEUTICS, INC. (0001434647) (Subject)

    11/12/24 5:59:21 PM ET
    $ZVRA
    Biotechnology: Pharmaceutical Preparations
    Health Care